Rapport Therapeutics Inc
RAPP27.350USD
+1.050+3.99%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
998.21MMarket Cap
LossP/E TTM
More Details of Rapport Therapeutics Inc Company
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a portfolio of precision small molecule product candidates. The Company focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. It advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.
Company Info
Ticker SymbolRAPP
Company nameRapport Therapeutics Inc
IPO dateJun 07, 2024
CEOMr. Abraham N. (Abe) Ceesay
Number of employees69
Security typeOrdinary Share
Fiscal year-endJun 07
Address99 High Street
CityBOSTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02110
Phone18573218020
Websitehttps://www.rapportrx.com/
Ticker SymbolRAPP
IPO dateJun 07, 2024
CEOMr. Abraham N. (Abe) Ceesay
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
789.71K
--
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Chairman of the Board
Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
426.64K
-1.95%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
--
Dr. Bradley S. Galer, M.D.
Dr. Bradley S. Galer, M.D.
Chief Medical Officer
Chief Medical Officer
111.42K
-43.56%
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Director
Director
--
--
Mr. Robert J. (Rob) Perez
Mr. Robert J. (Rob) Perez
Director
Director
--
--
Dr. James I. Healy, M.D., Ph.D.
Dr. James I. Healy, M.D., Ph.D.
Director
Director
--
--
Mr. Raymond Kelleher, M.D., Ph.D.
Mr. Raymond Kelleher, M.D., Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
789.71K
--
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Chairman of the Board
Chairman of the Board
477.64K
--
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
426.64K
-1.95%
Ms. Cheryl Gault
Ms. Cheryl Gault
Chief Operating Officer
Chief Operating Officer
171.93K
--
Dr. Bradley S. Galer, M.D.
Dr. Bradley S. Galer, M.D.
Chief Medical Officer
Chief Medical Officer
111.42K
-43.56%
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Chief Financial Officer
Chief Financial Officer
10.00K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
17.58%
Fidelity Management & Research Company LLC
11.87%
ARCH Venture Partners
8.09%
Cormorant Asset Management, LP
6.38%
Capital International Investors
5.64%
Other
50.45%
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
17.58%
Fidelity Management & Research Company LLC
11.87%
ARCH Venture Partners
8.09%
Cormorant Asset Management, LP
6.38%
Capital International Investors
5.64%
Other
50.45%
Shareholder Types
Shareholders
Proportion
Venture Capital
35.86%
Investment Advisor
30.72%
Hedge Fund
8.83%
Investment Advisor/Hedge Fund
5.34%
Individual Investor
5.01%
Research Firm
2.79%
Bank and Trust
0.55%
Insurance Company
0.01%
Pension Fund
0.01%
Other
10.89%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
154
43.38M
118.86%
+3.70M
2025Q1
149
47.96M
131.36%
+9.87M
2024Q4
117
46.27M
126.51%
+9.23M
2024Q3
91
39.09M
106.87%
+12.18M
2024Q2
48
37.49M
102.49%
+37.49M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Rock Ventures, LLC
8.10M
22.21%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.49M
15.03%
--
--
Mar 31, 2025
ARCH Venture Partners
3.73M
10.22%
--
--
Mar 31, 2025
Cormorant Asset Management, LP
2.94M
8.06%
--
--
Mar 31, 2025
Capital International Investors
2.60M
7.13%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.50M
6.84%
--
--
Mar 31, 2025
Sofinnova Investments, Inc
2.00M
5.47%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.05M
2.87%
-73.45K
-6.55%
Mar 31, 2025
Goldman Sachs & Company, Inc.
1.24M
3.41%
-7.83K
-0.63%
Mar 31, 2025
AllianceBernstein L.P.
1.11M
3.04%
+11.21K
+1.02%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Innovator US Small Cap Managed Floor ETF
0.04%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Morningstar Small-Cap ETF
0%
Innovator US Small Cap Managed Floor ETF
Proportion0.04%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
